Trials / Terminated
TerminatedNCT01575782
Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung Cancer
Chloroquine as an Anti-autophagic Radiosensitizing Drug in Stage I-III Small Cell Lung Cancer (SCLC) Patients: a Phase I Trial.
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Maastricht Radiation Oncology · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Chloroquine can make tumor cells less resistant to chemo/radiotherapy. In this trial chloroquine is given during radiotherapy. The dose is increased in cohorts of at least 3 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chloroquine | Daily intake of Chloroquine during radiotherapy |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2017-07-01
- Completion
- 2017-07-01
- First posted
- 2012-04-11
- Last updated
- 2017-07-18
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT01575782. Inclusion in this directory is not an endorsement.